1
|
Ando Y, Shimazaki H, Shiota K, Tetsuka S, Nakao K, Shimada T, Kurata K, Kuroda J, Yamashita A, Sato H, Sato M, Eto S, Onishi Y, Tanaka K, Kato S. Prevalence of elevated serum anti-N-methyl-D-aspartate receptor antibody titers in patients presenting exclusively with psychiatric symptoms: a comparative follow-up study. BMC Psychiatry 2016; 16:226. [PMID: 27391811 PMCID: PMC4938931 DOI: 10.1186/s12888-016-0948-9] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/24/2015] [Accepted: 06/13/2016] [Indexed: 01/17/2023] Open
Abstract
BACKGROUND Increasing numbers of patients with elevated anti-N-methyl-D-aspartate (NMDA) receptor antibody titers presenting exclusively with psychiatric symptoms have been reported. The aim of the present study was to clarify the prevalence of elevated serum anti-NMDA receptor antibody titers in patients with new-onset or acute exacerbations of psychiatric symptoms. In addition, the present study aimed to investigate the association between elevated anti-NMDA receptor titers and psychiatric symptoms. METHODS The present collaborative study included 59 inpatients (23 male, 36 female) presenting with new-onset or exacerbations of schizophrenia-like symptoms at involved institutions from June 2012 to March 2014. Patient information was collected using questionnaires. Anti-NMDA receptor antibody titers were measured using NMDAR NR1 and NR2B co-transfected human embryonic kidney (HEK) 293 cells as an antigen (cell-based assay). Statistical analyses were performed for each questionnaire item. RESULTS The mean age of participants was 42.0 ± 13.7 years. Six cases had elevated serum anti-NMDA antibody titers (10.2 %), four cases were first onset, and two cases with disease duration >10 years presented with third and fifth recurrences. No statistically significant difference in vital signs or major symptoms was observed between antibody-positive and antibody-negative groups. However, a trend toward an increased frequency of schizophrenia-like symptoms was observed in the antibody-positive group. CONCLUSION Serum anti-NMDA receptor antibody titers may be associated with psychiatric conditions. However, an association with specific psychiatric symptoms was not observed in the present study. Further studies are required to validate the utility of serum anti-NMDA receptor antibody titer measurements at the time of symptom onset.
Collapse
Affiliation(s)
- Yoshihito Ando
- Department of Neurology, Haga Red Cross Hospital, 2461 Daimachi, Moka, Tochigi, 321-4306, Japan. .,Division of Neurology, Department of Internal Medicine, Jichi Medical university, Shimotsuke, Tochigi, Japan.
| | - Haruo Shimazaki
- Division of Neurology, Department of Internal Medicine, Jichi Medical university, Shimotsuke, Tochigi Japan
| | - Katsutoshi Shiota
- Department of Psychiatry, Jichi Medical University, Shimotsuke, Tochigi Japan
| | - Syuichi Tetsuka
- Department of Neurology, International University of Health and Welfare Hospital, Nasushiobara, Tochigi Japan
| | - Koichi Nakao
- Department of Neurology, Junwakai Memorial Hospital, Miyazaki, Japan
| | - Tatsuhiro Shimada
- Department of Psychiatry, Tochigi Prefectural Okamotodai Hospital, Utsunomiya, Tochigi Japan
| | - Kazumi Kurata
- Department of Psychiatry, Jichi Medical University, Shimotsuke, Tochigi Japan ,Department of Psychiatry, Tochigi Prefectural Okamotodai Hospital, Utsunomiya, Tochigi Japan
| | - Jinichi Kuroda
- Department of Psychiatry, Tochigi Prefectural Okamotodai Hospital, Utsunomiya, Tochigi Japan
| | | | - Hayato Sato
- Department of Psychiatry, Sato Hospital, Yaita, Tochigi Japan
| | - Mamoru Sato
- Department of Psychiatry, Jichi Medical University, Shimotsuke, Tochigi Japan ,Department of Psychiatry, Kamitsuga General Hospital, Kanuma, Tochigi Japan
| | - Shinkichi Eto
- Department of Psychiatry, Kamitsuga General Hospital, Kanuma, Tochigi Japan
| | - Yasunori Onishi
- Department of Psychiatry, Oyama Fujimidai Hospital, Shimotsuke, Tochigi Japan
| | - Keiko Tanaka
- Department of Life Science, Medical Research Institute and Department of Neurology, Kanazawa Medical University, Uchinada, Ishikawa Japan
| | - Satoshi Kato
- Department of Psychiatry, Jichi Medical University, Shimotsuke, Tochigi Japan ,Department of Psychiatry, Oyama Fujimidai Hospital, Shimotsuke, Tochigi Japan
| |
Collapse
|
2
|
Idova GV, Alperina EL, Cheido MA. Contribution of brain dopamine, serotonin and opioid receptors in the mechanisms of neuroimmunomodulation: Evidence from pharmacological analysis. Int Immunopharmacol 2012; 12:618-25. [DOI: 10.1016/j.intimp.2012.02.010] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2011] [Revised: 02/20/2012] [Accepted: 02/22/2012] [Indexed: 01/11/2023]
|
3
|
Yang C, Chen Y, Tang L, Wang ZJ. Haloperidol disrupts opioid-antinociceptive tolerance and physical dependence. J Pharmacol Exp Ther 2011; 338:164-72. [PMID: 21436292 DOI: 10.1124/jpet.110.175539] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Previous studies from our laboratory and others have implicated a critical role of Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) in opioid tolerance and dependence. Translational research targeting the CaMKII pathway is challenging, if not impossible, because of a lack of selective inhibitors. We discovered in a preliminary study that haloperidol, a butyrophenone antipsychotic drug, inhibited CaMKII, which led us to hypothesize that haloperidol can attenuate opioid tolerance and dependence by inhibiting CaMKII. The hypothesis was tested in two rodent models of opioid tolerance and dependence. Pretreatment with haloperidol (0.2-1.0 mg/kg i.p.) prevented the development of morphine tolerance and dependence in a dose-dependent manner. Short-term treatment with haloperidol (0.06-0.60 mg/kg i.p.) dose-dependently reversed the established morphine-antinociceptive tolerance and physical dependence. Correlating with behavioral effects, pretreatment or short-term treatment with haloperidol dose-dependently inhibited morphine-induced up-regulation of supraspinal and spinal CaMKIIα activity. Moreover, haloperidol given orally was also effective in attenuating morphine-induced CaMKIIα activity, antinociceptive tolerance, and physical dependence. Taken together, these data suggest that haloperidol attenuates opioid tolerance and dependence by suppressing CaMKII activity. Because haloperidol is a clinically used drug that can be taken orally, we propose that the drug may be of use in attenuating opioid tolerance and dependence.
Collapse
Affiliation(s)
- Cheng Yang
- Department of Biopharmaceutical Sciences and Cancer Center, University of Illinois, Chicago, Illinois 60612, USA
| | | | | | | |
Collapse
|
4
|
Abstract
This paper is the thirtieth consecutive installment of the annual review of research concerning the endogenous opioid system. It summarizes papers published during 2007 that studied the behavioral effects of molecular, pharmacological and genetic manipulation of opioid peptides, opioid receptors, opioid agonists and opioid antagonists. The particular topics that continue to be covered include the molecular-biochemical effects and neurochemical localization studies of endogenous opioids and their receptors related to behavior, and the roles of these opioid peptides and receptors in pain and analgesia; stress and social status; tolerance and dependence; learning and memory; eating and drinking; alcohol and drugs of abuse; sexual activity and hormones, pregnancy, development and endocrinology; mental illness and mood; seizures and neurologic disorders; electrical-related activity and neurophysiology; general activity and locomotion; gastrointestinal, renal and hepatic functions; cardiovascular responses; respiration and thermoregulation; and immunological responses.
Collapse
Affiliation(s)
- Richard J Bodnar
- Department of Psychology and Neuropsychology Doctoral Sub-Program, Queens College, City University of New York, 65-30 Kissena Blvd.,Flushing, NY 11367, United States.
| |
Collapse
|